Prescription medicine
Ulipristal Brand names: Ella
Ulipristal (Ella) is a prescription medicine with an FDA approval on record since 2010. No generic is listed; pharmacies paid $37.10 per Ella 30 mg tablet in the October 7, 2026 NADAC survey.
- No generic listed
Check it at the source: the ulipristal FDA label on DailyMed (effective July 20, 2026, PMI Branded Pharmaceuticals, Inc.); the NDA 22474 record on Drugs@FDA; every ulipristal label on DailyMed.
Highlights of the record
FDA label of July 20, 2026; NDC Directory, Drugs@FDA and Orange Book, October 8, 2026; NADAC October 7, 2026
Used for
From the label: indications and usageElla is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see Dosage and Administration (2.1) ].
Forms and strengths
- 30 mg
Tablet.
On the market
- Earliest approval on file
- August 13, 2010 Ella, Lab Hra Pharma; Drugs@FDA’s file, where older or withdrawn approvals can be missing
- Generic approvals
- 1 first February 13, 2017; 1 with a marketed status in Drugs@FDA
- Labelers listed (NDC)
- 2 of which 0 under generic applications, 2 under brand applications, repackagers included
- Last listed patent
- June 12, 2030 Ella tablets; not a generic launch date
Supply and safety
- Pharmacy cost (NADAC)
- $37.10 per tablet Ella 30 mg tablet
- Shortage (FDA)
- No current entry
- Recalls by its makers (FDA)
- No recall recorded
- FAERS reports
- 504 through July 30, 2026
What is ulipristal used for?
From the label: indications and usageElla is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure [see Dosage and Administration (2.1) ]. Ella is not intended for routine use as a contraceptive. Ella is a progesterone agonist/antagonist emergency contraceptive indicated for prevention of pregnancy following unprotected intercourse or a known or suspected contraceptive failure. Ella is not intended for routine use as a contraceptive.
Conditions named in the indications of ulipristal's FDA labels, with every medicine labeled for each:
FDA pharmacologic class: Progesterone Agonist/Antagonist.
Source: FDA drug label (Ella), PMI Branded Pharmaceuticals, Inc., effective July 20, 2026 (SPL set 2bf93d23-cddd-4613-9066-5b5fa090404b), via openFDA; the full label on DailyMed
Is there a generic for ulipristal (Ella)?
The FDA approved the first generic ulipristal on February 13, 2017. 1 generic application is approved; 1 of it carries a current (not discontinued) marketing status in Drugs@FDA; that status is not evidence that the generic is on sale.
The Orange Book lists 8 patents for Ella tablets, the last expiring on June 12, 2030. A patent or exclusivity date is not the date a generic goes on sale: court cases and settlements move it either way.
- 2010 earliest approval on file
- 2017 first generic approved
- 2030 last listed patent
Source: Drugs@FDA, FDA NDC Directory and the Orange Book (openFDA bulk files, October 8, 2026)
What do pharmacies pay for ulipristal (Ella)?
In CMS's NADAC survey of October 7, 2026, pharmacies paid $37.10 per Ella 30 mg tablet, about the same as a year earlier. The chart's scale runs from the lowest to the highest price shown, not from zero. NADAC is what retail pharmacies paid their wholesalers, per unit, in CMS's monthly survey; what a patient pays depends on insurance and the pharmacy.
- Ella 30 mg tablet (brand)
| Strength and form | Brand or generic | Pharmacy cost | 30 tablets, or one pen or vial | 12-month change |
|---|---|---|---|---|
| Ella 30 mg tablet | Brand | $37.10 per tablet | $1,112.94 | no change |
Source: CMS National Average Drug Acquisition Cost (NADAC) survey, October 7, 2026: what retail pharmacies paid per unit; not a counter price
What does the ulipristal label say about other medicines?
The ulipristal label names 6 other medicines in its interaction, contraindication or warning sections. The labels of 3 other medicines name ulipristal. The sentences are the labels' own; a label lists what its studies and reports found, not every interaction.
| Medicine named | Section | What the label says |
|---|---|---|
| Carbamazepine | drug interactions | carbamazepine |
| Itraconazole | drug interactions | Concentrations of ella Associated with Co-Administered Drugs CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella [see Pharmacokinetics (12.3) ]. |
| Ketoconazole | drug interactions | Concentrations of ella Associated with Co-Administered Drugs CYP3A4 inhibitors such as itraconazole or ketoconazole increase plasma concentrations of ella [see Pharmacokinetics (12.3) ]. |
| Oxcarbazepine | drug interactions | oxcarbazepine |
| Rifampin | warnings and precautions | CYP3A4 Inducers A CYP3A4 inducer, rifampin, decreases the plasma concentration of ella significantly. |
| Topiramate | drug interactions | topiramate Hormonal contraceptives Progestin-containing contraceptives may impair the ability of ella to delay ovulation. |
Other labels that name ulipristal
Source: FDA drug label (Ella), PMI Branded Pharmaceuticals, Inc., effective July 20, 2026 (SPL set 2bf93d23-cddd-4613-9066-5b5fa090404b), via openFDA; the full label on DailyMed
What do FAERS reports show for ulipristal?
The FDA Adverse Event Reporting System holds 504 reports that list ulipristal among the medicines taken, through July 30, 2026, each a report of something that happened, not proof the medicine caused it; 2 are coded as a death and 69 as a hospital stay. Counts follow how widely a medicine is used and watched, and they are not a measure of how risky it is.
Reports received each year
The most reported reactions
Source: FDA Adverse Event Reporting System (FAERS) via openFDA, reports through July 30, 2026
What else is labeled for the same conditions as ulipristal?
6 other medicines are given the same way (oral) and in the same FDA class as ulipristal or labeled mainly for the same use (birth control), the same class first. Birth control lists all 24 medicines labeled for it, by any route. They are listed as records, not as substitutes: whether one can replace another is a prescriber's decision.
| Medicine | Shared indication | Generic labelers (oral) | Pharmacy cost | Shortage |
|---|---|---|---|---|
| Levonorgestrel | Birth control | 33 labelers | $6.33 per tablet 1.5 mg tablet | No current entry |
| Ethinyl estradiol and norethindrone | Birth control | 15 labelers | $0.181 per tablet 21 1-20 tablet | No current entry |
| Norethindrone | Birth control | 17 labelers | $0.290 per tablet 5 mg tablet | No current entry |
| Ethinyl estradiol and levonorgestrel | Birth control | 4 labelers | $0.154 per tablet 28 tablet | No current entry |
| Ethinyl estradiol and ferrous fumarate and norethindrone | Birth control | 2 labelers | $0.142 per tablet 1.5-30 tablet | No current entry |
| Ethinyl estradiol and norgestrel | Birth control | 2 labelers | $0.302 per tablet 28 tablet | No current entry |
Every medicine labeled for the same conditions as ulipristal
Source: FDA drug labels (indications), NDC Directory, NADAC of October 7, 2026, FDA shortages (October 8, 2026)
What next?
- Alternatives to ulipristal
- 6 medicines for the same use
- Ulipristal side effects
- the label's list beside FAERS reports
- Check an interaction
- what two or more labels say about each other